ABSTRACT
Evidence that lead poses hazards even at relatively low exposure levels is mounting. As a result, the methods used to estimate the monetary value of the benefits of reducing these exposures need to be improved and updated, so that these benefits can be compared to the costs of potential new control strategies. In previous regulatory analyses, the most significant quantifiable benefits included the effects of lead-related neurological damage on future earnings and lead’s effect on the risk of premature mortality from cardiovascular disease. However, many of the monetary values are now outdated. In addition, recent assessments include a large number of additional benefit categories that could be included in future regulatory analyses.
